eCART vs MyoVista wavECG
A hospital nursing or quality lead scoring ward patients for deterioration would look at AgileMD, whose eCART has held K233253 since June 2024 and which reports 400+ hospitals. A cardiology group would look at HeartSciences for 12-lead ECG review once an algorithm is cleared. The two do not compete for the same purchase. HeartSciences received 510(k) clearance for the MyoVista wavECG, a 12-lead resting ECG, on October 5, 2026 (K260005), and the clearance leaves out the AI-ECG algorithm. The company says it does not intend to commercialize the device without a cleared algorithm and gives no timeline, so it has no cleared AI product today. Its site describes MyoVista Insights as a device-agnostic ECG management system for third-party AI-ECG models and says its AI-ECG products are not commercially available in the United States. A business combination with Fortitude Mining Holdings is expected to close in the fourth quarter of 2026. Neither vendor publishes a price.
Decision support · Reviewed November 2, 2026
eCART
by AgileMD
Early warning software that scores hospitalized ward patients for risk of deterioration from EHR data, for use by trained clinicians.
MyoVista wavECG
by HeartSciences
12-lead resting ECG device for cardiology clinics, FDA 510(k) cleared in October 2026 without its AI-ECG algorithm.
When to pick each one
eCART
- FDA-cleared ward deterioration score since June 2024
- Vendor reports 400+ hospitals
MyoVista wavECG
- 12-lead resting ECG cleared October 2026, K260005
- Vendor describes device-agnostic ECG management
Score
Each row shows points earned of points available under the published rubric.
eCART
56of 100
MyoVista wavECG
31of 100
| Dimension | eCART | MyoVista wavECG | Difference |
|---|---|---|---|
| FDA clearance | 12 / 12 | 12 / 12 | 0 |
| HIPAA / SOC2 / BAA | 10 / 10 | 6 / 10 | +4 |
| EHR integrations (count) | 0 / 5.6 | 1.7 / 5.6 | -1.7 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 4.8 | 1.9 / 4.8 | -1.9 |
| Bidirectional write-back | 0 / 1.2 | 0 / 1.2 | 0 |
| Peer-reviewed papers | 21 / 21 | 0 / 21 | +21 |
| RCT / meta-analysis / systematic review | 0 / 9 | 0 / 9 | 0 |
| Funding & adoption signal | 3 / 12 | 3 / 12 | 0 |
| Pricing transparency | 1.3 / 2.5 | 1.3 / 2.5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
eCART
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. There is no pricing page; the site offers a demo request only. |
MyoVista wavECG
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Evidence
eCART
FDA decisions
K233253 (opens in new tab)510(k)2024-06-21
eCARTv5 Clinical Deterioration Suite (eCART)
Peer-reviewed
5 PubMed records name eCART.
- Early Warning Scores With and Without Artificial Intelligence. (opens in new tab)
- Multicenter Development and Prospective Validation of eCARTv5: A Gradient Boosted Machine Learning Early Warning Score. (opens in new tab)
- DETERIO-LLM: enhancing traditional deterioration risk scores with clinical context and advanced reasoning. (opens in new tab)
MyoVista wavECG
FDA decisions
K260005 (opens in new tab)510(k)2026-10-05
MyoVista wavECG (DG-200-B15-003)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | eCART | MyoVista wavECG |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Epic |
| Founded | n/a | n/a |
| HQ | US | US |
Scroll horizontally to see both columns.
Common questions
Open the full decision support comparison
Differential diagnosis, treatment guidance, drug interactions, evidence-grounded Q&A. The CDS landscape ranges from the UpToDate gold standard to physician-only OpenEvidence. We compared what clinicians actually use.